Introduction: Pemetrexed is a treatment option for advanced non-small cell lung cancer. In the product information of Pemetrexed, conjunctivitis is described as a common side effect; other eye disorders are not described. However, in daily clinical practice we have experienced that patients treated with Pemetrexed describe different kinds of eye disorders during their course of treatment. These eye disorders may have a negative impact on patient quality of life (QoL). Objectives: The purpose of the study is to identify the kind of eye disorders patients experience during the treatment with Pemetrexed, how many patients experience the eye disorders, and grade the detected eye disorders according to Common Toxicity Criteria for Adverse Event version 4.0 (CTCAE). Methods: This is a retrospective study of patients treated with Pemetrexed in the Department of Oncology, Odense University Hospital, Denmark from 1st January 2013 to 31st December 2014. Data are obtained from patient files. Results: During the study period 264 patients were treated with Pemetrexed. Half of the patients 132 experienced eye disorders. The observed eye disorders were dry eyes, tear flow, stinging eyes, materie in the eyes, blurred vision, redding and swelling of skin under the eyes and unspecific eye disorders. Grade 1 eye disorders were experienced by 34 patients, grade 2 by 133. None experienced grade 3. Conclusions: Eye disorders are an underestimated side effect from Pemetrexed. There is a need for increased attention to this side effect in order to initiate treatment and maintain QoL of the patient during the palliative treatment with Pemetrexed. (Figure Presented).
Supportive Care in Cancer, 2015, Vol 23, Issue SUPPL. 1
*side effect *human *retrospective study *neoplasm *eye disease patient eye non small cell lung cancer tear flow blurred vision conjunctivitis Denmark oncology toxicity quality of life university hospital clinical practice dry eye palliative therapy swelling skin *pemetrexed; *rehabilitation *cancer patient *human *neoplasm rehabilitation center patient heart disease quality of life cardiac patient solid mortality learning hospitalization diagnosis economic aspect cancer survivor; *head and neck cancer *radiation *neoplasm mucosa inflammation risk proportional hazards model acceleration human regression analysis log rank test patient radiotherapy intensity modulated radiation therapy; *hypothyroidism *radiotherapy *neoplasm thyroid gland neck human patient risk factor surgery radiation radiation dose planning model chemotherapy breast cancer subclinical hypothyroidism Hodgkin disease head and neck squamous cell carcinoma data extraction treatment planning thyroid function risk prediction tissues; *osteoporosis *chemotherapy *breast cancer *neoplasm *risk human patient osteolysis hip spine adjuvant chemotherapy secondary osteoporosis radius bone density Fisher exact test cohort analysis drug therapy fracture cancer patient forearm absorptiometry X ray imaging cancer chemotherapy prednisolone corticosteroid marker calcium vitamin D; *overall survival *patient *human *neoplasm *Charlson Comorbidity Index stereotactic body radiation therapy comorbidity lung cancer non small cell lung cancer scoring system medical record review physician survival control group histology gender follow up smoking tumor volume data base; *febrile neutropenia *cancer patient *human *neoplasm male female chemotherapy patient cerebrospinal fluid drug dose reduction risk aged prostate diagnosis Denmark prospective study ovary cancer university hospital oncology retrospective study density prognosis adverse drug reaction *granulocyte colony stimulating factor; *neoplasm *risk human chemotherapy quality of life cancer survivor prevention single nucleotide polymorphism peripheral neuropathy predictive value side effect genomics glove detoxification genotype gene DNA repair genetic variability patient toxicity platinum derivative enzyme DNA; *salivary gland function *radiation dose *salivary gland *radiotherapy *head and neck cancer *neoplasm salivation xerostomia stimulus chewing gum radiotherapy planning system side effect flow rate questionnaire prescription drug megadose human patient submandibular gland pilot study food saliva sugar; *human *phase 1 clinical trial *neoplasm *patient *rectum cancer *neuropathy *prevention neurotoxicity chemotherapy allodynia infusion peripheral neuropathy safety phase 2 clinical trial antineoplastic activity adverse drug reaction model toxicity experience controlled study *placebo oxaliplatin fluorouracil protective agent; *central venous catheter *bloodstream infection *therapy *acute lymphoblastic leukemia *cohort analysis *Denmark *neoplasm human patient risk child attributable risk diagnosis death pediatric hospital confidence interval population high risk population neutropenia Gram positive infection; *hospital infection *neoplasm human patient oncology ward infection ward risk urinary tract diarrhea disease control bacteremia safety health care pneumonia serum hospitalization infection control surgical ward mouth hygiene prevention immune system; *human *cancer patient *neoplasm *spouse *radiotherapy *head and neck cancer patient diseases physician child friend hospital memory nutrition information processing; *neoplasm *human *vein thrombosis *patient thrombosis cancer patient risk questionnaire morbidity lung cancer cancer prevention death male prevention female; *overall survival *radiotherapy *non small cell lung cancer *neoplasm human patient survival radiation chemotherapy histology lung function thorax tumor squamous cell carcinoma lung cancer gender world health organization; *hospital *neoplasm pathogen load microorganism microbiology colony forming unit hospital infection photometer oncology ward *adenosine triphosphate marker; *rehabilitation *interview *oncology ward *nursing *neoplasm human nurse patient intuition hospitalization oral communication hematology ward skill oncology verbal communication communication skill nursing competence questionnaire interpersonal communication; *radiotherapy *cohort analysis *larynx cancer *cancer patient *human *neoplasm *tobacco use smoking lowest income group diagnosis statistics head and neck cancer data base diseases tobacco primary tumor treatment response prognosis logistic regression analysis Denmark risk tobacco consumption patient world health organization; *myeloma *patient *human *neoplasm survival morbidity death kidney failure diagnosis scoring system quality of life hope disease severity infection; *human *neoplasm *nurse *patient *skill *sexuality *hematology *oncology sexual dysfunction conversation health practitioner prevalence sexual orientation society cancer therapy interview sexual function literature counseling coping behavior